Developer docs
API playgroundTry for free, no card

Search company profiles

Tanner Pharma

Full company profile

uuid0006h4d

Namestring
Tanner Pharma
Legal namestring
Tanner Pharma Group, Inc.
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Tanner Pharma Group, Inc. is a privately-held pharmaceutical services company founded in 1999 by Banks Bourne and headquartered in Charlotte, NC. The firm operates through three core service lines delivered under wholly-owned subsidiaries: TannerLAC (licensing, acquisitions, and commercialization for emerging markets), TannerGAP (global access programs including named-patient supply, compassionate use, and early access), and TannerCTS (clinical trial sourcing of comparators, bioanalytical, and biologic products, plus secondary packaging and labeling). Together these address the global access gap affecting nearly 2 billion people who lack access to essential medicines, providing compliant pathways for biopharmaceutical sponsors to reach patients in markets where treatments are not commercially available, have been withdrawn, or face supply shortages.

The company's core technology is a GDP-compliant pharmaceutical distribution and supply-chain platform combining temperature-controlled cold-chain logistics (2-8°C), EPCIS-enabled real-time product tracking, EDI systems integration for order processing, and a quality management system aligned with regulatory standards across multiple jurisdictions. Tanner maintains licensed operations in the US (NCAGR), UK (MHRA GDP and MIA(IMP)), Ireland (HPRA wholesaler and MIA), and Switzerland (Swissmedic establishment), with distribution reach extending to 155+ countries via owned warehouses and contracted logistics partners. Differentiated capabilities include cold-chain clinical-trial supply for biologics and rare-disease therapies, secondary packaging and labeling, comparator drug sourcing, and real-world data capture alongside access-program delivery.

Tanner generates revenue through a B2B enterprise sales motion targeting biopharmaceutical companies, clinical trial sponsors, healthcare providers, NGOs, and ministries of health. Revenue streams span professional services (program management and regulatory compliance fees for access programs), managed services (sourcing, packaging, and logistics for clinical trials), and transaction fees (commercial distribution, tender supply, and importation). Pricing is bespoke and quote-based with no public disclosure; revenue allocation includes a charitable contribution through the TannerCares program. The company is founder-controlled, privately held with no disclosed institutional funding, and operates 101-250 employees across the US, UK, Ireland, and Switzerland.

Short descriptiontext

Tanner Pharma is a privately-held pharma services company that designs and operates global access programs, clinical trial supply chains, and licensed pharmaceutical distribution for biopharma sponsors across 155+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCharlotte, United States
HQ citystring
Charlotte
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical access solutions, clinical trial supply services, named patient programs, comparator drug sourcing, compassionate use services
Industry3 codes
PRIMARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution
NAICS code2 codes
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceutical Access Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Access Solutions Services
TypeProfessional Services
Description

Provides compliant pharmaceutical access solutions including compassionate use programs, named patient programs, market withdrawal support, and emergency supply services to biopharmaceutical companies. Revenue generated through service fees for program management, regulatory compliance, and distribution services.

tannerpharma.com
2Clinical Trial Solutions
TypeManaged Services
Description

Comparator drug sourcing, procurement, secondary packaging, labeling, and GDP-compliant storage and distribution for clinical trials. Revenue from sourcing fees, logistics services, and value-added packaging services.

tannerpharma.com
3Commercial Distribution
TypeTransaction Fee
Description

Global pharmaceutical distribution including tender supply, commercial importation, and ongoing supply to hospitals, pharmacies, and ministries of health.

tannerpharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Tanner Pharma provides global pharmaceutical access solutions and clinical trial supply chain services for biopharmaceutical companies. Its core offerings include compassionate use, named patient, and protocol-based access programs, post-trial and donation programs, market withdrawal/shortage response, and commercial distribution/tender supply under its Access Solutions business. Its Clinical Trial Solutions cover comparator drug sourcing and procurement of bioanalytical/biologic materials, secondary packaging, labeling and kitting, and GDP-compliant temperature-controlled storage and distribution across 155+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 30,000 patients reached through global donation program across 80 countries
+4 more records
Product and service7 records
1Access Solutions
CategoryPharmaceutical Access Services
Description

Compliant, tailored access solutions that remove treatment barriers and deliver therapies to patients worldwide; covers compassionate use, named patient and protocol-based access programs, post-trial supply, donation programs, market withdrawal/shortage response, and commercial distribution. Serves biopharmaceutical companies ranging from emerging biotech to global pharma that need to deliver therapies in markets without marketing authorization.

2Clinical Trial Solutions
CategoryClinical Trial Supply Services
Description

End-to-end clinical trial supply chain services for life sciences innovators, including comparator drug sourcing and procurement of bioanalytical/biologic materials, secondary packaging/labeling/kitting, GDP-compliant temperature-controlled storage and distribution, and urgent packaging rework. Serves clinical trial sponsors and biotech companies running multi-country trials.

3Compassionate Use and Named Patient Programs
CategoryPharmaceutical Access Services
Description

Programs that provide individual patients with access to investigational or unauthorized medicines on a named-patient or compassionate use basis, managed compliantly across regulatory jurisdictions. Used by biopharmaceutical companies and treating physicians when no authorized alternative exists.

4Comparator Drug Sourcing and Procurement
CategoryClinical Trial Supply Services
Description

Sourcing of comparator drugs and bioanalytical/biologic reference materials for clinical trials across global markets, including multi-lot and multi-country procurement under tight timelines. Used by clinical trial sponsors and CROs running Phase II-III studies.

5Cold-Chain Clinical Trial Supply (2-8°C)
CategoryClinical Trial Supply Services
Description

GDP-compliant, temperature-controlled (2-8°C) storage and distribution of clinical trial materials with specialized courier solutions across multiple countries. Used by sponsors of temperature-sensitive biologics and advanced therapy trials.

6Medicine Donation Programs
CategoryPharmaceutical Access Services
Description

Compliant design, management, and distribution of pharmaceutical donation programs targeting underserved patient populations in low- and middle-income countries. Used by NGOs, ministries of health, and biopharmaceutical donors supporting access to chronic and rare disease therapies.

7eRapa Global Early Access Program
CategoryEarly Access Programs
Description

Global Early Access/Named Patient Program for eRapa, an investigational oral therapy for Familial Adenomatous Polyposis (FAP). Delivered in partnership with Biodexa Pharmaceuticals to provide compliant, controlled access to the investigational therapy in countries where it is not commercially available, while generating Real World Data.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

Strategic partnership to launch a global Early Access/Named Patient Program for eRapa, an investigational oral therapy for Familial Adenomatous Polyposis (FAP). Tanner Pharma facilitates compliant, controlled access to eRapa in countries where it is not commercially available. Biodexa generates Real World Data as part of the initiative. This is the first time the investigational medicine will be prescribed outside of clinical trials.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global clinical trial supply services company providing comparator sourcing, packaging, labeling, and distribution for clinical trials — directly comparable to Tanner's Clinical Trial Solutions division.

TypeDirect peer
Description

UK-based global pharmaceutical services company specializing in managed access programs (named patient, compassionate use), clinical trial supply, and unlicensed medicines — directly overlapping Tanner's access solutions and clinical trial supply offerings.

TypeBroad incumbent
Description

Largest global CRO and clinical trial services provider with broad capabilities in clinical supply, commercial distribution, and real-world evidence — overlaps with Tanner across multiple service lines but at much greater scale.

TypeBroad incumbent
Description

Through Patheon and clinical supply services, offers comparator sourcing, packaging, labeling, and global distribution — broad incumbent in clinical trial supply adjacent to Tanner's CTS offerings.

TypeDirect peer
Description

Specializes in comparator sourcing and clinical trial supply for the pharmaceutical industry, with a focus on difficult-to-source medicines — directly comparable to Tanner's TannerCTS comparator sourcing business.

6McKesson
TypeBroad incumbent
Description

Major pharmaceutical wholesaler and specialty distribution operator with global reach and access services — broad incumbent whose specialty distribution business overlaps with Tanner's commercial distribution segment.

TypeOthers
Description

Global logistics provider with GDP-compliant pharmaceutical distribution and cold chain capabilities — comparable as a contracted logistics partner and infrastructure provider supporting Tanner's broader 3PL network.

TypeBroad incumbent
Description

One of the largest pharmaceutical distributors globally with specialty distribution, patient access services, and consulting — overlaps with Tanner's commercial distribution and access solutions but at vastly greater scale.

TypeDirect peer
Description

Specialty pharmaceutical distributor focused on patient access programs, rare disease therapies, and limited distribution drugs — comparable to Tanner's TannerGAP and TannerLAC access-focused businesses.

10RxLogix
TypeEmerging player
Description

Provides patient access, named patient program, and safety case management technology for pharmaceutical companies — partial overlap with Tanner's digital and operational infrastructure for access programs.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tanner Pharma

Pharmaceutical Access Servicestannerpharma.com

Tanner Pharma is a privately-held pharma services company that designs and operates global access programs, clinical trial supply chains, and licensed pharmaceutical distribution for biopharma sponsors across 155+ countries.

What Tanner Pharma does

Tanner Pharma Group, Inc. is a privately-held pharmaceutical services company founded in 1999 by Banks Bourne and headquartered in Charlotte, NC. The firm operates through three core service lines delivered under wholly-owned subsidiaries: TannerLAC (licensing, acquisitions, and commercialization for emerging markets), TannerGAP (global access programs including named-patient supply, compassionate use, and early access), and TannerCTS (clinical trial sourcing of comparators, bioanalytical, and biologic products, plus secondary packaging and labeling). Together these address the global access gap affecting nearly 2 billion people who lack access to essential medicines, providing compliant pathways for biopharmaceutical sponsors to reach patients in markets where treatments are not commercially available, have been withdrawn, or face supply shortages.

The company's core technology is a GDP-compliant pharmaceutical distribution and supply-chain platform combining temperature-controlled cold-chain logistics (2-8°C), EPCIS-enabled real-time product tracking, EDI systems integration for order processing, and a quality management system aligned with regulatory standards across multiple jurisdictions. Tanner maintains licensed operations in the US (NCAGR), UK (MHRA GDP and MIA(IMP)), Ireland (HPRA wholesaler and MIA), and Switzerland (Swissmedic establishment), with distribution reach extending to 155+ countries via owned warehouses and contracted logistics partners. Differentiated capabilities include cold-chain clinical-trial supply for biologics and rare-disease therapies, secondary packaging and labeling, comparator drug sourcing, and real-world data capture alongside access-program delivery.

Tanner generates revenue through a B2B enterprise sales motion targeting biopharmaceutical companies, clinical trial sponsors, healthcare providers, NGOs, and ministries of health. Revenue streams span professional services (program management and regulatory compliance fees for access programs), managed services (sourcing, packaging, and logistics for clinical trials), and transaction fees (commercial distribution, tender supply, and importation). Pricing is bespoke and quote-based with no public disclosure; revenue allocation includes a charitable contribution through the TannerCares program. The company is founder-controlled, privately held with no disclosed institutional funding, and operates 101-250 employees across the US, UK, Ireland, and Switzerland.

Tanner Pharma firmographics

Firmographics
Name
Tanner Pharma
Legal name
Tanner Pharma Group, Inc.
Website
https://tannerpharma.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
101–250 employees
Short description
Tanner Pharma is a privately-held pharma services company that designs and operates global access programs, clinical trial supply chains, and licensed pharmaceutical distribution for biopharma sponsors across 155+ countries.
Ownership category
akta.pro rank

Tanner Pharma industry classification

Industry
Product category
Pharmaceutical Access Services
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution

Keywords

  • Pharmaceutical access solutions
  • Clinical trial supply services
  • Named patient programs
  • Comparator drug sourcing
  • Compassionate use services

Where Tanner Pharma is headquartered

Location

Headquarters

HQ city
Charlotte
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Tanner Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Access Solutions Services: Provides compliant pharmaceutical access solutions including compassionate use programs, named patient programs, market withdrawal support, and emergency supply services to biopharmaceutical companies. Revenue generated through service fees for program management, regulatory compliance, and distribution services.
  2. Clinical Trial Solutions: Comparator drug sourcing, procurement, secondary packaging, labeling, and GDP-compliant storage and distribution for clinical trials. Revenue from sourcing fees, logistics services, and value-added packaging services.
  3. Commercial Distribution: Global pharmaceutical distribution including tender supply, commercial importation, and ongoing supply to hospitals, pharmacies, and ministries of health.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Tanner Pharma product offering

Product offering

Core offering

Tanner Pharma provides global pharmaceutical access solutions and clinical trial supply chain services for biopharmaceutical companies. Its core offerings include compassionate use, named patient, and protocol-based access programs, post-trial and donation programs, market withdrawal/shortage response, and commercial distribution/tender supply under its Access Solutions business. Its Clinical Trial Solutions cover comparator drug sourcing and procurement of bioanalytical/biologic materials, secondary packaging, labeling and kitting, and GDP-compliant temperature-controlled storage and distribution across 155+ countries.

Differentiator

Problem solved

Functional benefit

Products and services

  • Access Solutions Compliant, tailored access solutions that remove treatment barriers and deliver therapies to patients worldwide; covers compassionate use, named patient and protocol-based access programs, post-trial supply, donation programs, market withdrawal/shortage response, and commercial distribution. Serves biopharmaceutical companies ranging from emerging biotech to global pharma that need to deliver therapies in markets without marketing authorization.
  • Clinical Trial Solutions End-to-end clinical trial supply chain services for life sciences innovators, including comparator drug sourcing and procurement of bioanalytical/biologic materials, secondary packaging/labeling/kitting, GDP-compliant temperature-controlled storage and distribution, and urgent packaging rework. Serves clinical trial sponsors and biotech companies running multi-country trials.
  • Compassionate Use and Named Patient Programs Programs that provide individual patients with access to investigational or unauthorized medicines on a named-patient or compassionate use basis, managed compliantly across regulatory jurisdictions. Used by biopharmaceutical companies and treating physicians when no authorized alternative exists.
  • Comparator Drug Sourcing and Procurement Sourcing of comparator drugs and bioanalytical/biologic reference materials for clinical trials across global markets, including multi-lot and multi-country procurement under tight timelines. Used by clinical trial sponsors and CROs running Phase II-III studies.
  • Cold-Chain Clinical Trial Supply (2-8°C) GDP-compliant, temperature-controlled (2-8°C) storage and distribution of clinical trial materials with specialized courier solutions across multiple countries. Used by sponsors of temperature-sensitive biologics and advanced therapy trials.
  • Medicine Donation Programs Compliant design, management, and distribution of pharmaceutical donation programs targeting underserved patient populations in low- and middle-income countries. Used by NGOs, ministries of health, and biopharmaceutical donors supporting access to chronic and rare disease therapies.
  • eRapa Global Early Access Program Global Early Access/Named Patient Program for eRapa, an investigational oral therapy for Familial Adenomatous Polyposis (FAP). Delivered in partnership with Biodexa Pharmaceuticals to provide compliant, controlled access to the investigational therapy in countries where it is not commercially available, while generating Real World Data.

Quantifiable outcome

  • 30,000 patients reached through global donation program across 80 countries
  • +4 more outcomes

Companies that use Tanner Pharma

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Tanner Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Tanner Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Biodexa Pharmaceuticals PLCcoreStrategic or Co-development Partner · 23 March 2026Strategic partnership to launch a global Early Access/Named Patient Program for eRapa, an investigational oral therapy for Familial Adenomatous Polyposis (FAP). Tanner Pharma facilitates compliant, controlled access to eRapa in countries where it is not commercially available. Biodexa generates Real World Data as part of the initiative. This is the first time the investigational medicine will be prescribed outside of clinical trials.

Scale indicators7 records

Recent moves5 records

Expansion highlights6 records

Tanner Pharma competitors and assessment

Company assessment

Direct peers

  • Myonex: Global clinical trial supply services company providing comparator sourcing, packaging, labeling, and distribution for clinical trials — directly comparable to Tanner's Clinical Trial Solutions division.
  • Clinigen Group: UK-based global pharmaceutical services company specializing in managed access programs (named patient, compassionate use), clinical trial supply, and unlicensed medicines — directly overlapping Tanner's access solutions and clinical trial supply offerings.
  • BAP Pharma: Specializes in comparator sourcing and clinical trial supply for the pharmaceutical industry, with a focus on difficult-to-source medicines — directly comparable to Tanner's TannerCTS comparator sourcing business.
  • AnovoRx: Specialty pharmaceutical distributor focused on patient access programs, rare disease therapies, and limited distribution drugs — comparable to Tanner's TannerGAP and TannerLAC access-focused businesses.

Broad incumbents

  • IQVIA: Largest global CRO and clinical trial services provider with broad capabilities in clinical supply, commercial distribution, and real-world evidence — overlaps with Tanner across multiple service lines but at much greater scale.
  • Thermo Fisher Scientific (Clinical Trial Services): Through Patheon and clinical supply services, offers comparator sourcing, packaging, labeling, and global distribution — broad incumbent in clinical trial supply adjacent to Tanner's CTS offerings.
  • McKesson: Major pharmaceutical wholesaler and specialty distribution operator with global reach and access services — broad incumbent whose specialty distribution business overlaps with Tanner's commercial distribution segment.
  • Cencora (formerly AmerisourceBergen): One of the largest pharmaceutical distributors globally with specialty distribution, patient access services, and consulting — overlaps with Tanner's commercial distribution and access solutions but at vastly greater scale.

Others

  • DHL Supply Chain (Life Sciences & Healthcare): Global logistics provider with GDP-compliant pharmaceutical distribution and cold chain capabilities — comparable as a contracted logistics partner and infrastructure provider supporting Tanner's broader 3PL network.

Emerging players

  • RxLogix: Provides patient access, named patient program, and safety case management technology for pharmaceutical companies — partial overlap with Tanner's digital and operational infrastructure for access programs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Tanner Pharma social profiles

Digital presence

Tanner Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tanner Pharma leadership team

Management profile

Number of profiles

Profiles2 records

Tanner Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Tanner Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tanner Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tanner Pharma

What does Tanner Pharma do?

Tanner Pharma provides global pharmaceutical access solutions and clinical trial supply chain services for biopharmaceutical companies. Its core offerings include compassionate use, named patient, and protocol-based access programs, post-trial and donation programs, market withdrawal/shortage response, and commercial distribution/tender supply under its Access Solutions business. Its Clinical Trial Solutions cover comparator drug sourcing and procurement of bioanalytical/biologic materials, secondary packaging, labeling and kitting, and GDP-compliant temperature-controlled storage and distribution across 155+ countries.

Is Tanner Pharma a public or private company?

Tanner Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Tanner Pharma founded?

Tanner Pharma was founded in 1999. It employs 101 to 250 people.

Where is Tanner Pharma based?

Tanner Pharma is headquartered in Charlotte, United States, in the North America region.

How does Tanner Pharma make money?

Three revenue lines are on record. Access Solutions Services are the primary driver. The others are clinical Trial Solutions and commercial Distribution.

Who are Tanner Pharma's main competitors?

Direct peers on record are Myonex, Clinigen Group, BAP Pharma and AnovoRx. Broad incumbents are IQVIA, Thermo Fisher Scientific (Clinical Trial Services), McKesson and Cencora (formerly AmerisourceBergen). DHL Supply Chain (Life Sciences & Healthcare) is listed as an others. RxLogix is listed as an emerging player.

Does Tanner Pharma have an API?

No public API is recorded for Tanner Pharma.

What industry is Tanner Pharma in?

Tanner Pharma's product category is Pharmaceutical Access Services. Its primary akta.pro industry code is HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant), with a secondary code of HLAIAJAB, Specialty Pharmaceutical Distributors. Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceInterim results for the six months ended June 30, 2026Biodexa Pharmaceuticals reported interim results for the six months ended June 30, 2026, with R&D costs rising to £2.92 million and net cash used in operating activities of £4.61 million. The company raised $3.5 million in financing on July 1, 2026, and its cash balance at period end was £3.23 million.Stock TitanBiodexa, Tanner launch eRapa access program for FAPTanner Pharma Group and Biodexa Pharmaceuticals have launched a global Early Access Program for eRapa, an investigational oral capsule formulation of rapamycin, to treat patients with Familial Adenomatous Polyposis (FAP). The program enables clinicians to prescribe the therapy outside of clinical trials for the first time and will generate Real World Data to advance understanding of FAP and patient experience. FAP currently has no approved therapeutic option, with surgical resection remaining the standard of care.BioSpaceTanner Pharma Group and Biodexa Launch Global Early Access Program for FAP PatientsTanner Pharma Group and Biodexa Pharmaceuticals announced a strategic partnership to launch a global Early Access/Named Patient Program for eRapa, an investigational oral therapy for Familial Adenomatous Polyposis (FAP), a rare disease characterized by polyp proliferation in the colon and rectum with no approved therapeutic option. Through this collaboration, Tanner Pharma will facilitate compliant, controlled access to eRapa in countries where it is not commercially available, allowing clinicians to prescribe the investigational therapy outside clinical trials for the first time. Biodexa will also generate Real World Data as part of the initiative to further advance understanding of FAP and patient experience.Investing.comBiodexa partners with Tanner Pharma for FAP drug early access By Investing.comBiodexa Pharmaceuticals PLC announced a partnership with Tanner Pharma Group to provide its investigational drug eRapa to Familial Adenomatous Polyposis patients through a global Early Access Program, enabling clinicians to prescribe the medicine outside clinical trials for the first time. FAP is a rare genetic condition with no approved therapeutic options, affecting approximately 1 in 5,000 to 10,000 people in the United States and 1 in 11,300 to 37,600 in Europe. The company is also conducting a double-blind Phase 3 registrational trial across 30 sites in the US and Europe, supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas.Stock TitanBiodexa, Tanner launch eRapa early access for FAPBiodexa Pharmaceuticals has entered into a strategic partnership with Tanner Pharma Group to launch a global Early Access Program for eRapa, an investigational mTOR inhibitor treatment for Familial Adenomatous Polyposis, allowing clinicians to prescribe the drug outside clinical trials for the first time. The program will be open globally to appropriate patients subject to local legislation and funding availability, with Biodexa generating Real World Data on FAP patient outcomes. FAP is a rare hereditary condition affecting 1 in 5,000-10,000 people in the US with no currently approved therapeutic options, making this initiative significant for patients who currently rely on surgical intervention as standard of care.GlobeNewswireBiodexa Launches Global Early Access Program for eRapa forBiodexa Pharmaceuticals PLC has launched a Global Early Access Program for its investigational drug eRapa, targeting patients with Familial Adenomatous Polyposis, through a strategic partnership with Tanner Pharma Group to enable clinicians to prescribe the drug outside of clinical trials for the first time. The program will be available globally subject to local regulations and funding, and Biodexa will simultaneously generate Real World Data on FAP patients. A Phase 3 registrational trial is planned across 30 sites in the US and Europe, enrolling 168 patients and supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas.AETOSWireTanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With AgenusTanner Pharma and Agenus announced a collaboration to provide expanded access to botensilimab and balstilimab through a Named Patient Program for patients with microsatellite stable colorectal cancer and other advanced solid tumors. The program allows access before regulatory approval, with Tanner Pharma managing access in geographies permitting named patient access.TannerpharmaTanner PharmaTanner Pharma Group presents its mission to improve lives by increasing access to medicines worldwide, citing nearly 2 billion people lacking essential medicines. The company highlights client work including Leukine distribution for Partner Therapeutics, free cancer treatment distribution for The Max Foundation, Latin American distribution, pandemic-era comparator sourcing, and a new US facility.PR NewswireElevar Therapeutics and Tanner Pharma Group Announce Global Named Patient Program to Provide Access to Apealea® (paclitaxel micellar)Elevar Therapeutics and Tanner Pharma Group announced a partnership to provide global named patient access to Apealea (paclitaxel micellar) in regions outside the United States where the drug is not yet commercially available. Under this agreement, Tanner will serve as the exclusive supplier for healthcare providers, facilitating early access for patients with specific cancers who have no other therapeutic alternatives. This initiative complements Elevar's existing European approvals and its strategy to identify regional commercialization partners worldwide.GlobeNewswireMannKind and Tanner Pharma Group Enter into an ex-U.S. Distribution Agreement for Afrezza®MannKind and Tanner Pharma Group announced a distribution agreement for Afrezza, an inhaled insulin, outside the U.S. Tanner will distribute the product in regions where it is not yet registered. The deal aims to expand access in underserved international markets.